Molecular structure of Erdafitinib, CAS Number: 1346242-81-6
Erdafitinib (CAS 1346242-81-6)
Alternate Names:
Erdafitinib JNJ-42756493 JNJ42756493 JNJ 42756493 Balversa UNII-890E37NHMV
CAS Number:
1346242-81-6
Molecular Weight:
446.60
Molecular Formula:
C25H30N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Erdafitinib (CAS 1346242-81-6) References
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. | Loriot, Y., et al. 2019. N Engl J Med. 381: 338-348. PMID: 31340094
- Erdafitinib to treat urothelial carcinoma. | Hanna, KS. 2019. Drugs Today (Barc). 55: 495-501. PMID: 31461086
- Erdafitinib for the treatment of urothelial cancer. | Marandino, L., et al. 2019. Expert Rev Anticancer Ther. 19: 835-846. PMID: 31544541
- Erdafitinib for the treatment of metastatic bladder cancer. | Montazeri, K. and Bellmunt, J. 2020. Expert Rev Clin Pharmacol. 13: 1-6. PMID: 31810398
- Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. | Roubal, K., et al. 2020. Am J Health Syst Pharm. 77: 346-351. PMID: 32073123
- Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. | Siefker-Radtke, AO., et al. 2022. Lancet Oncol. 23: 248-258. PMID: 35030333
- Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations. | Franza, A., et al. 2022. Future Oncol. 18: 2455-2464. PMID: 35387485
- Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. | Pant, S., et al. 2023. Lancet Oncol. 24: 925-935. PMID: 37541273
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. | Loriot, Y., et al. 2023. N Engl J Med. 389: 1961-1971. PMID: 37870920
- Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. | Siefker-Radtke, AO., et al. 2024. Ann Oncol. 35: 107-117. PMID: 37871702
Inhibitor of:
Bek, bFGF, Cnpy1, FGF-2, FGFR, FGFR-3, FGFR-4, FGFR1OP2, FIBP, FIGNL1, Flg, FRRS1, FRS3, GFR-1, Olr1169, and Type II 5-phosphatase.Activator of:
PRAT4B_Cnpy4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Erdafitinib, 10 mg | sc-507388 | 10 mg | $138.00 |